A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexate

Arana Therapeutics Ltd0 个研究点目标入组 200 人开始时间: 2009年1月6日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Arana Therapeutics Ltd
入组人数: 200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Valid written informed consent.
•2. Male or female subjects = 18 and = 80 years old.
•3. Women of childbearing potential, or men of fathering potential, must be using adequate birth control measures during the study.
•Female subjects of childbearing potential must test negative for pregnancy prior to enrolling in the study.
•Post menopausal women are eligible for this study.
•4. Diagnosis of RA for at least 6 months and no longer than 3 years prior to screening.
•5. Meet ACR functional class criteria I, II or III.
•6. Have active RA at the time of screening and at baseline, defined as = 6 swollen joints and = 6 tender joints (from 68 joint count) together with at least 2 of the following 3 criteria:
•-CRP level = 1.5 mg/dl;
•-ESR by Westergren method = 28 mm in the first hour; or
•-morning stiffness = 45 minutes.
•7. At least one should be present at screening:
•-documented history or current presence of positive rheumatoid factor;
•- presence of serum anti-CCP antibodies; or screening radiographic erosion.
•8. Have been tolerating concomitant methotrexate (oral or subcutaneous) for at least 3 months prior to screening and on a stable dose between 10-25 mg per week for at least 6 weeks prior to the first study dose. The route of administration must also be stable. Use of methotrexate dose of 25-50 mg every 2 weeks is also acceptable. (Other DMARDs taken concomitantly with methotrexate are not allowed. Those subjects concomitantly receiving additional DMARDs with methotrexate may enter the study by stopping the additional DMARD at least 4 weeks prior to first study dose).
•9. If using the following medication, the subject must be on a stable dose for the 4 weeks prior to the first study dose and maintain that dose throughout the study:
•-oral corticosteroids, equivalent to = 10 mg of prednisone/day.
•-one nonsteroidal anti-inflammatory drug (NSAID).
•-3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates (see Protocol Section 7.1 for acceptable doses).
•10. Does not have active or latent TB according to eligibility assessment and screening rules
•11. Is willing and able to comply with study visits and other protocol requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Pregnant, nursing, or planning a pregnancy (both men and women) within 9 months of enrolment.
•2. Subjects weighing > 100 kgs.
•3. Screening laboratory tests:
•-hemoglobin = 8.0 gm/dl
•-white blood cells = 3.0 x103 cells/µl
•-neutrophils = 1.5 x 103 cells/µl
•-platelets =100 x 103 cells/µl
•-serum transaminase level (AST and ALT) = 2 times upper limit of normal (ULN)
•-serum creatinine = 0.15 mmol/l
•4. Subjects with diagnosis of juvenile arthritis or other inflammatory or autoimmune diseases that might confound the evaluations of benefit from ART621 such as ankylosing spondylitis, systemic lupus erythematosus and Lyme disease.
•5. Subjects who have previously failed to respond to any oral or injectable anti-TNFa therapy or subjects who have had to stop anti-TNFa therapy for safety reasons. Subjects who have successfully responded to anti-TNF therapy in the past (but discontinued for reasons other than safety or lack of efficacy) > 6 months prior to study day one may enrol. Patients who have participated in a previous anti-TNF therapy study are eligible if they are confirmed to have received placebo.
•6. Subjects who have previously received the following anti-rheumatic drugs: interleukin-1 receptor antagonist [anakinra], rituximab, anti-CD4 antibody, abatacept, thalidomide, p38 MAP kinase inhibitor and other agents.
•7. Subjects who have undergone plasmapheresis within 6 months prior to randomisation.
•8. Have received intraarticular, intramuscular, or intravenous corticosteroids, including intramuscular adrenocorticotropic hormone, during the 4 weeks prior to the first study dose, or non-stable doses of oral steroids.
•9. Subjects with a history of any clinically significant adverse reaction to murine or chimeric proteins, including serious allergic reactions.
•10. Subjects with Felty’s syndrome or a history of Felty’s syndrome.
•11. Subjects who have received or are expecting to receive any live virus or bacterial vaccinations within 1 month before first study dose, during the study, or up to 3 months after the study dose.
•12. Subjects with a history of, presence of, or at high risk of serious infection including:
•-history of active TB, or positive Mantoux test or QuantiFERON Gold test or chest x-ray suggestive of active or healed TB or positive contact history with a subject with active TB within the past 3 months. If patients have a positive Mantoux test but a negative QuantiFERON Gold test, they may be enrolled.
•-a serious infection during the 3 months prior study entry (hospitalised or received IV antibiotics for an infection).
•-chronic or recurrent infectious disease.
•-systemic fungal infections.
•-opportunistic infection within 3 months prior to screening.
•-subjects known, or suspected, to be infected with HIV, hepatitis B, or hepatitis C.
•-subjects with planned joint replacement surgery or a history of infected joint prosthesis or who have received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.
•13. Subjects with a known history of demyelinating diseases such as multiple sclerosis or optic neuritis.
•14. Subjects with evidence of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease.
•15. Concurrent CHF, including medically controlled, asymptomatic CHF or ECG findings suggestive of CHF.
•16. Subjects receiving cytotoxic drugs including cyclophosphamide, cyclospo

研究者

发起方

Arana Therapeutics Ltd

相似试验

进行中（未招募）

1 期

Tranexamic Acid use in patients that suffering severe injury that is associated with excessive bleeding and coagulation disorderTrauma patients with risk for acute traumatic Coagulopathy and HemorrhageMedDRA version: 20.1Level: LLTClassification code 10044528Term: Traumatic injurySystem Organ Class: 100000004863

EUCTR2019-004118-33-DEniversität Witten/Herdecke1,316

Unknown

2 期

A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexate

CTRI/2009/091/000569Arana Therapeutics Limited Level 2, 37 Epping Road Macquarie Park NSW 2113 AUSTRALIA200

进行中（未招募）

不适用

A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2Rheumatoid arthritis

EUCTR2007-003508-36-DEitec Pharma AG350

进行中（未招募）

不适用

EUCTR2007-003508-36-HUitec Pharma AG350

进行中（未招募）

1 期

EUCTR2007-003508-36-GBitec Pharma AG